Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 1;15(4):4827–4836. doi: 10.3892/ol.2018.7922

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Fu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — NP-visnagin targeted to the reperfused myocardium and exerted cardioprotective effects. (A) Following the intravenous injection of PBS (baseline), FITC or NP-FITC, in vivo BLI was performed at each time point. (B) Quantitative analysis of BLI data for NP-FITC compared with FITC alone. (C) Fluorescence images of heart cross-sections at 12 h after the intravenous injection of PBS, FITC or NP-FITC. (D) Quantification of the fluorescence intensity of the non-ischemic myocardium and AAR. (E) Representative stereomicrographs of heart sections double stained with TTC and Evans blue at 72 h after intravenous injection. (F) Quantitative analysis of IF/AAR. (G) Quantitative analysis of AAR/LV. *P<0.05; ***P<0.005. NP, nanoparticles; FITC, fluorescein isothiocyanate; BLI, bioluminescence imaging; TTC, 2,3,5-triphenyltetrazolium chloride; IF, infarct area; AAR, area at risk; LV, left ventricle; NS, not significant.